Asston Pharmaceuticals
ASSTONPHARMACEUTICALSLTD NSE
Asston Pharmaceuticals
Capital GoodsNSE: ASSTONPHARMACEUTICALSLTD BSE: 544445 Other Electrical Equipment
Key Fundamentals
SMEOther Electrical EquipmentCapital GoodsMarket Cap
₹117 Cr
Volatility
Moderate
P/E Ratio
30.2
EBITDA
₹-0.56 Cr
Return on Equity
34.91%
Debt to Equity
0.13
Book Value
₹60.96
52W High
₹126.1
52W Low
₹60
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.6.12 Cr.
- Company has high debtors of 524 days.
- Working capital days have increased from 259 days to 434 days
Growth Rate
Revenue Growth
-0.51% lower than
3Y
Net Income Growth
1.79% lower than
3Y
Cash Flow Change
99.24% higher than
3Y
ROE
64.05% higher than
3Y
ROCE
32.28% higher than
3Y
EBITDA Margin (Avg.)
-108% higher than
3Y
Quarterly Results
| Particulars | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 15.97 | 9.07 | 15.42 | 10.05 |
| Expenses | 13.71 | 5.89 | 13.19 | 12.85 |
| Operating Profit | 2.26 | 3.18 | 2.23 | -2.8 |
| OPM % | 14.15% | 35.06% | 14.46% | -27.86% |
| Other Income | 0.64 | -0.07 | -1.86 | 4.63 |
| Interest | 0.42 | 0.53 | 0.28 | 0.36 |
| Depreciation | 0.02 | 0.02 | 0.07 | 0.25 |
| PBT | 2.46 | 2.56 | 0.02 | 1.22 |
| Tax % | 22.76% | 23.44% | -50% | 59.84% |
| Net Profit | 1.9 | 1.95 | 0.03 | 0.48 |
| EPS in Rs | 24.24 | 3.11 | 0.04 | 0.56 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 9.6 | 6.54 | 16.03 | 25.04 | 25.47 |
| Expenses | 9.96 | 5.02 | 12.21 | 19.6 | 26.04 |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.57 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.24% |
| Other Income | 0.96 | 0.65 | 0.25 | 0.57 | 6.12 |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| PBT | 0.16 | 1.41 | 3.25 | 5.02 | 4.6 |
| Tax % | 31.25% | 25.53% | 25.23% | 23.11% | 15.87% |
| Net Profit | 0.11 | 1.06 | 2.43 | 3.85 | 3.87 |
| EPS in Rs | 1.57 | 15.14 | 31 | 6.14 | 4.55 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.7 | 0.7 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.4 | 4.76 | 30.35 |
| Borrowings | 3.31 | 5.24 | 6.82 | 7.25 | 5.11 |
| Other Liabilities | 5.25 | 6.46 | 6.7 | 9.84 | 7.68 |
| Total Liabilities | 9.49 | 13.69 | 20.7 | 28.12 | 51.65 |
| Fixed Assets | 0.92 | 1.13 | 0.97 | 0.96 | 10.69 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8.57 | 12.56 | 19.73 | 27.16 | 40.96 |
| Total Assets | 9.49 | 13.69 | 20.7 | 28.12 | 51.65 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | -1.19 | -0.32 | -3.97 | -0.03 | -10.18 |
| Investing | 0 | -0.91 | -0.01 | 0.73 | -9.91 |
| Financing | 1.29 | 1.21 | 3.86 | -0.51 | 21.18 |
| Net Cash Flow | 0.1 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | -0.06 | -20.24 |
| CFO/OP | 322 | -20 | -92 | 0 | 1,368 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 243 | 481 | 381 | 358 | 524 |
| Inventory Days | 27.24 | 204 | 53.91 | 18.59 | 16.14 |
| Days Payable | 247 | 755 | 218 | 154 | 121 |
| Cash Conversion Cycle | 23.79 | -69.7 | 217 | 222 | 419 |
| Working Capital Days | -12.17 | 43.53 | 163 | 179 | 434 |
| ROCE % | — | 37.14% | 37.78% | 36.62% | 16.8% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Asston Pharmaceuticals insights
58 extracted metrics + investor summaries across FY22–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024. 30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024. 30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024.
3
Shareholder Meeting / Postal Ballot-Outcome of EGM
28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors. 28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors.
5
Shareholder Meeting / Postal Ballot-Outcome of EGM
28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors. 28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors.
Frequently Asked Questions about Asston Pharmaceuticals
What does Asston Pharmaceuticals Ltd do?
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
Where is Asston Pharmaceuticals Ltd (544445) listed?
Asston Pharmaceuticals Ltd trades as ASSTONPHARMACEUTICALSLTD on the NSE and under code 544445 on the BSE.
Which sector does Asston Pharmaceuticals Ltd belong to?
Asston Pharmaceuticals Ltd is classified under the Capital Goods sector, in the Other Electrical Equipment industry.
What is the market capitalisation of Asston Pharmaceuticals Ltd?
Asston Pharmaceuticals Ltd has a market capitalisation of ₹116.9 Cr, which places it in the Small Cap band.
What is the PE ratio of Asston Pharmaceuticals Ltd?
Asston Pharmaceuticals Ltd trades at a PE ratio of 30.20, against a book value of ₹60.96 per share.
What is the 52-week high and low of Asston Pharmaceuticals Ltd?
Over the last 52 weeks Asston Pharmaceuticals Ltd has traded between ₹60 and ₹126.1.
What is the Return on Equity (ROE) of Asston Pharmaceuticals Ltd?
Asston Pharmaceuticals Ltd reported a return on equity of 34.91%. Its debt-to-equity ratio is 0.13.
Company Information
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544445.md for Asston Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.